Survival benefit added by adjuvant chemotherapy in adenoid cystic carcinoma of salivary gland.
Adenoid cystic carcinoma
Chemoradiotherapy
Prognosis
Radiotherapy
Salivary gland cancer
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 10 2024
28 10 2024
Historique:
received:
26
05
2024
accepted:
21
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
The aim of this study was to investigate the potential survival advantages associated with chemoradiotherapy (CRT) compared to radiotherapy (RT) as standalone modalities in the treatment of adenoid cystic carcinoma (ACC) of the salivary glands. Patients diagnosed with resected salivary gland ACC were retrospectively enrolled and categorized into two groups based on the type of adjuvant therapy received. The overall survival outcomes between the CRT and RT cohorts were evaluated using a multivariable Cox model. Post propensity score-matching, a total of 114 patients (57 in each treatment group) were included in the analysis. In the general patient population, CRT did not confer an additional survival benefit compared to RT alone. High-grade tumors, positive surgical margins, and the presence of five or more positive lymph nodes were identified as independent prognostic factors associated with poorer overall survival. Specifically, for patients with positive surgical margins, CRT was significantly associated with improved overall survival relative to RT, displaying a hazard ratio of 0.93 (95% CI: 0.81-0.99). Furthermore, in patients with more than four metastatic lymph nodes, CRT significantly reduced the risk of mortality by 6% (95% CI: 1-24%) when compared to RT alone. Conversely, in patients with high-grade tumors, the addition of adjuvant chemotherapy to RT did not yield significant alterations in survival outcomes compared to RT alone (p = 0.437, HR: 0.95, 95% CI: 0.75-2.07). CRT may offer an overall survival benefit for patients with salivary gland ACC, particularly those characterized by positive margin or the presence of five or more metastatic lymph nodes.
Identifiants
pubmed: 39468317
doi: 10.1038/s41598-024-77296-8
pii: 10.1038/s41598-024-77296-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25746Informations de copyright
© 2024. The Author(s).
Références
Kacew, A. J. & Hanna, G. J. Systemic and targeted therapies in Adenoid cystic carcinoma. Curr. Treat. Options Oncol. 24, 45–60 (2023).
doi: 10.1007/s11864-022-01043-2
pubmed: 36637743
Zupancic, M., Näsman, A., Friesland, S. & Dalianis, T. Adenoid Cystic Carcinoma, clinical presentation, current treatment and approaches towards Novel therapies. Anticancer Res. 44, 1325–1334 (2024).
doi: 10.21873/anticanres.16929
pubmed: 38537991
Caudell, J. J. et al. NCCN Guidelines® insights: Head and Neck cancers, Version 1.2022. J. Natl. Compr. Canc Netw. 20, 224–234 (2022).
doi: 10.6004/jnccn.2022.0016
pubmed: 35276673
Geiger, J. L. et al. Management of salivary gland malignancy: ASCO Guideline. J. Clin. Oncol. 39, 1909–1941 (2021).
doi: 10.1200/JCO.21.00449
pubmed: 33900808
von der Grün, J. et al. Patterns of care analysis for salivary gland cancer: a survey within the German Society of Radiation Oncology (DEGRO) and recommendations for daily practice. Strahlenther Onkol. 198, 123–134 (2022).
doi: 10.1007/s00066-021-01833-x
pubmed: 34427717
Bernier, J. et al. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl. J. Med. 350, 1945–1952 (2004).
doi: 10.1056/NEJMoa032641
pubmed: 15128894
Cooper, J. S. et al. Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl. J. Med. 350, 1937–1944 (2004).
doi: 10.1056/NEJMoa032646
pubmed: 15128893
Bernier, J. et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 27, 843–850 (2005).
doi: 10.1002/hed.20279
pubmed: 16161069
Meyers, M. et al. REFCOR members. Head and neck adenoid cystic carcinoma: a prospective multicenter REFCOR study of 95 cases. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 133, 13–17 (2016).
doi: 10.1016/j.anorl.2015.09.009
pubmed: 26493113
Qiu, Z. et al. Platinum-based adjuvant chemoradiotherapy versus adjuvant radiotherapy in patients with head and neck adenoid cystic carcinoma. J. Cancer Res. Clin. Oncol. 150, 195 (2024).
doi: 10.1007/s00432-024-05719-0
pubmed: 38625410
pmcid: 11021222
Fang, Q. et al. Neck management in cutaneous squamous cell carcinoma with parotid metastasis. Head Neck. 46, 1938–1945 (2024).
doi: 10.1002/hed.27676
pubmed: 38334480
Schanne, D. H., Alder, D. U., Lippmann, J., Aebersold, D. M. & Elicin, O. Effect of dose to parotid ducts on Sticky Saliva and Xerostomia in radiotherapy of head and neck squamous cell carcinoma. Radiat. Oncol. 19, 104 (2024).
doi: 10.1186/s13014-024-02495-6
pubmed: 39095864
pmcid: 11295643
Little, R. A test of missing completely at random for multivariable data with missing values. J. Am. Stat. Assoc. 83, 1198–1202 (1988).
doi: 10.1080/01621459.1988.10478722
van Buuren, S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat. Methods Med. Res. 16, 219–242 (2007).
doi: 10.1177/0962280206074463
pubmed: 17621469
Bhushan, K., Sharma, M. L. & Gupta, D. K. Chemotherapy for salivary gland malignant carcinoma: Meta-analysis and systemic review. Indian J. Otolaryngol. Head Neck Surg. 76, 123–129 (2024).
doi: 10.1007/s12070-023-04104-6
pubmed: 38440426
Amini, A. et al. Association of Adjuvant Chemoradiotherapy vs Radiotherapy alone with survival in patients with resected major salivary gland carcinoma: data from the National Cancer Data Base. JAMA Otolaryngol. Head Neck Surg. 142, 1100–1110 (2016).
doi: 10.1001/jamaoto.2016.2168
pubmed: 27541166
Cheraghlou, S. et al. Adjuvant therapy in major salivary gland cancers: analysis of 8580 patients in the National Cancer Database. Head Neck. 40, 1343–1355 (2018).
doi: 10.1002/hed.24984
pubmed: 29756412
Gordon, A. J. et al. Adoption of adjuvant chemotherapy in high-risk salivary gland malignancies. Head Neck. 45, 167–177 (2023).
doi: 10.1002/hed.27222
pubmed: 36245302
Aro, K. et al. Survival impact of adjuvant therapy in Salivary Gland Cancers following Resection and Neck Dissection. Otolaryngol. Head Neck Surg. 160, 1048–1057 (2019).
doi: 10.1177/0194599819827851
pubmed: 30721113
Hsieh, C. E. et al. Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. Radiat. Oncol. 11, 47 (2016).
doi: 10.1186/s13014-016-0617-7
pubmed: 27000157
pmcid: 4802842
Shimoda, H. et al. Prognostic scores for patients with salivary adenoid cystic carcinoma without lymph node metastasis. Oral Oncol. 145, 106491 (2023).
doi: 10.1016/j.oraloncology.2023.106491
pubmed: 37487445
Han, F. Number of positive lymph nodes affects outcomes in parotid adenoid cystic carcinoma. Front. Oncol. 13, 1153186 (2023).
doi: 10.3389/fonc.2023.1153186
pubmed: 37035205
pmcid: 10076875
Zumsteg, Z. S. et al. Quantitative lymph node burden as a ‘very-high-risk’ factor identifying head and neck cancer patients benefiting from postoperative chemoradiation. Ann. Oncol. 30, 76–84 (2019).
doi: 10.1093/annonc/mdy490
pubmed: 30395159